ArticleTranslational gastroenterology and hepatology2025
Lymph node metastases status in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: a single-center cross-sectional study.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Minimally Invasive Esophagectomy-An Overview of Recent Developments and a Novel Classification of Innovations in Treatment of Thoracic Esophageal Cancer.Medicina (Kaunas, Lithuania) · 2025Review
- Reassessing the prognostic value of station 108 in the era of neoadjuvant therapy.International journal of surgery (London, England) · 2025Article
- Transcriptome analysis and artificial intelligence for predicting lymph node metastasis of esophageal squamous cell carcinoma.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The status of lymph node (LN) metastases in esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoradiation (NCRT) is not well understood but significantly affects patient prognosis and treatment options. We conducted this study to evaluate the distribution of LN metastases in patients with ESCC who received NCRT combined minimally invasive esophagectomy (MIE). Methods: From March 2019 to September 2023, patients with middle- and lower-third ESCC received NCRT, followed by MIE with two-field lymphadenectomy, were included in this study. The primary outcome was to examine the distribution of LN metastases and their correlation with the radiation fields. Secondary outcomes included identifying risk factors for LN metastases and their impact on long-term survival. Results: One hundred consecutive patients were included, and 4.11% had LN metastases. The median number of positive LN and the rate of LN metastases in the thoracic LN stations was lower than that of the abdominal region (1.5 and 2.84% Conclusions: In patients with middle- and lower-third ESCC who underwent NCRT followed by MIE, the rate of LN metastases in the abdominal region is higher than in the thoracic region. The majority of patients had LN metastases within the radiation field. Therefore, NCRT does not justify minimizing lymphadenectomy in ESCC; furthermore, a higher ycN-stage correlated with a higher incidence of LN metastases; higher ycN-stage correlates with higher LN metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.